logo
logo

Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation Biologics

Harbour BioMed Raises $102.8M in Series C Financing to Accelerate Development of Its Innovative Portfolio of Next Generation Biologics

07/09/20, 11:01 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgcambridge
Money raised
$102 million
Industry
biotechnology
Round Type
series c
Harbour BioMed (HBM) today announced completion of its Series C financing of $102.8 Million to accelerate development of its growing portfolio of next generation biologics targeting cancer, immunologic diseases, and COVID-19. The financing was led by new investors, Hudson Bay Capital, followed by OrbiMed, Country Garden VC, GTJA Investment Group, Octagon Capital, and Sage Partners, with additional investment from existing investor Greater Bay Area Investment Fund. The round follows a $75 million Series B+ financing the Company completed in March 2020.

Company Info

Company
Harbour BioMed
Location
cambridge, massachusetts, united states
Additional Info
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.

Related People